A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Overview of attention for article published in Journal of Translational Medicine, November 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 1 news story.

NewLink Genetics (NASDAQ: NLNK ) is a small biopharmaceutical company (market cap: $347.84 million) developing novel immuno-oncol…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.